The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
102 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Read Publications using NB100-68264 in the following applications:
Based on 100% sequence identity, this antibody is predicted to react with Orangutan, Chimpanzee, White-tufted-ear marmoset, Crab-eating macaque, African elephant, Small-eared galago, Little brown bat and Northern white-cheeked gibbon.
Alternate Names for CIP2A Antibody
Cancerous inhibitor of PP2A
CIP2A (cancerous inhibitor of PP2A) was originally identified as p90, a cytoplasmic autoantigen found in the serum from a cancer patient. It was later described as a protein that interacted with the c-myc oncogene and functioned as an inhibitor of protein phosphatase 2A (PP2A) activity. Inhibition of PP2A phosphatase activity by CIP2A prevents c-myc phosphorylation and counteracts c-myc proteolytic degradation, thereby stabilizing c-myc and promoting cell growth and transformation. CIP2A is found to be over expressed in some human malignancies and is thus classified as an oncogene that may be an important contributor to tumor formation.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
CIP2A - A lean, mean, oncoprotein machine The CIP2A protein was originally identified as p90, a cytoplasmic auto-antigen from the serum of a cancer patient. It was later found to inhibit protein phosphatase 2A (PP2A) activity as well as interact with c-myc. CIP2A's inhibitory activity blocks... Read full blog post.